

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 7th July 2021

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia			✓	Decision deferred to confirm with NICE place in therapy in those whose dose of statin cannot be increased to usually max recommended dose.
2) New Requests				
Nil this month				
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis				The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE did not recommend use.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis	✓ R			The formulary will reflect the TAG – CCGs are the responsible commissioner.
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	✓ R			The formulary will reflect the TAG – CCGs are the responsible commissioner.
7) Appeals against earlier decisions by the APC				
None				
8) Products considered by NTAG				
Nil this month				
8) Miscellaneous formulary decisions by the APC				
Minoxidil 5% foam for hair loss – to add to formulary as NOT APPROVED.	✓ BLACK	✓		To add to DNP list as a cosmetic product and not a good all use of NHS resources. All other topical forms of minoxidil are blacklisted in the Drug Tariff. Patients can buy OTC or be prescribed privately.

The following guidelines were presented to and approved at the July 2021 meeting of the APC:

- TEWV STOMP medication pathway
- TEWV Depression pathway (updated): updated version approved.
- TEWV Anxiety pathway (updated): updated version approved.
- TEWV Adult ADHD algorithm (updated): updated version received for information.

DECISION SUMMARY

- TEWV Childrens ADHD algorithm (updated): updated version received for information.
- Psoriatic arthritis pathway: updated version approved to include of guselkumab as per NICE TA.

The following shared care guidelines were presented to and approved at the July 2021 meeting of the APC:

- Nil this month

Other documents presented to and approved at the July 2021 meeting of the APC:

- North Yorkshire & York APC Declarations of Interest Policy
- North Yorkshire & York APC Shared Care Template
- North Yorkshire & York APC Cover Sheet Template for Agenda Items